MilliporeSigma Increases Global Commitment to Biosafety Testing With € 35 Million Investment in Scotland
NEWS RELEASE
- Responds to global demand for biosafety testing for drug development and commercialization
- Expansion creates nearly 500 new jobs in Glasgow and Stirling
- Company’s investment to boost global testing capacity now tops € 350 million since mid-2022
Burlington, Massachusetts, May 31, 2023 - MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that its Life Science business sector is investing € 35 million in biosafety testing at its Glasgow and Stirling sites in Scotland. Biosafety testing is a critical step in the drug development and manufacturing process that ensures drugs are safe, efficacious, and meet regulatory requirements. The expansion will create nearly 500 new jobs, bringing the company’s workforce to over 1,200 employees across the two sites.
“We remain committed to ensuring the safety of the world's medicines through our state-of-the-art testing solutions for our customers around the world that drive new treatments,” said Dirk Lange, Head of Life Science Services, MilliporeSigma. “Since mid-2022, we have announced investments of more than € 350 million in our global testing network to meet the growing demand for these services.”
The centerpiece of the investment is a new, 1,200-square-meter facility in Glasgow, which will house molecular biology and sequencing services. The company will expand testing capacity in its current buildings with biosafety testing, analytical development, and viral clearance suites. The latest investment follows the company’s recent Rockville, Maryland, USA, and Shanghai, China testing expansions.
“Merck KGaA, Darmstadt, Germany has a wealth of testing expertise spanning over 75 years, including 33 years here in Scotland,” said David McClelland, Site Head and Managing Director for the Scottish sites. “The biosafety testing services at our sites in Glasgow and Stirling have been experiencing strong, double-digit growth for several years. This investment is a significant announcement for us in Scotland and an acknowledgment of the great work of our on-site teams.”
With its BioReliance® testing services portfolio, Merck KGaA, Darmstadt, Germany performs more than 20,000 studies in the UK annually for more than 500 clients globally.
BioReliance® Contract Testing Services and the recently formed Millipore® CTDMO Services are part of the Life Science Services business unit, which together with the Process Solutions business is one of the “Big 3” growth drivers of Merck KGaA, Darmstadt, Germany. The company aims to increase its Group sales to approximately € 25 billion by 2025. Around 80% of the planned sales growth is to come from the “Big 3” businesses.
About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck KGaA, Darmstadt, Germany, generated sales of € 22.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.
Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Contact
Rachel Bloom-Baglin
Email: rachel.bloom-baglin@milliporesigma.com
Phone: +1 978-436-1725
Últimas notas de prensa
Para seguir leyendo, inicie sesión o cree una cuenta.
¿No tiene una cuenta?